Pasithea Therapeutics Corp. (KTTA)

NASDAQ: KTTA · IEX Real-Time Price · USD
7.15
+0.25 (3.62%)
Mar 27, 2024, 12:00 AM EDT - Market open

Company Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases.

It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers.

Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications.

The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia.

Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Pasithea Therapeutics Corp.
Pasithea Therapeutics logo
Country United States
Founded 2020
IPO Date Sep 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Dr. Tiago Reis Marques M.D., Ph.D.

Contact Details

Address:
2110 Narcissus Ct
Venice, California 90291
United States
Phone (818) 422-6172
Website pasithea.com

Stock Details

Ticker Symbol KTTA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001841330
CUSIP Number 70261F103
ISIN Number US70261F2020
Employer ID 85-1591963
SIC Code 2834

Key Executives

Name Position
Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder, MD and Executive Chairman
Dr. Tiago Reis Marques M.D., Ph.D. Chief Executive Officer and Director
Daniel H. Schneiderman Chief Financial Officer
Dr. Yassine Bendiabdallah Ph.D. Chief Operating Officer and Head of UK Clinics
Dr. Graeme Currie Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Jan 18, 2024 8-K Current Report
Jan 2, 2024 8-K Current Report
Dec 28, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Dec 28, 2023 8-K Current Report
Dec 19, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Dec 19, 2023 8-K Current Report
Nov 29, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 13, 2023 10-Q Quarterly Report
Oct 26, 2023 ARS Filing
Oct 26, 2023 DEF 14A Other definitive proxy statements